Literature DB >> 10844971

Development of glaucoma after cataract surgery in dogs: 220 cases (1987-1998).

D J Biros1, K N Gelatt, D E Brooks, P S Kubilis, S E Andrew, D T Strubbe, H M Whigham.   

Abstract

OBJECTIVE: To examine postoperative ocular hypertension (POH) and other variables as predictors of the risk of developing glaucoma after cataract surgery in dogs.
DESIGN: Retrospective study. ANIMALS: 220 dogs that had cataract surgery. PROCEDURE: Medical records of 220 dogs (346 eyes) that had extracapsular cataract removal or phacoemulsification of cataracts were reviewed. With respect to glaucoma development, 8 variables were analyzed, which included development of POH, breed, sex, age at time of surgery, eye (right vs left), phacoemulsification time, intraocular lens (IOL) placement (yes or no), and stage of cataract development. Eyes developed glaucoma within 6 or 12 months of surgery or did not have signs of glaucoma at least 6 or 12 months after cataract surgery.
RESULTS: Of 346 eyes, 58 (16.8%) developed glaucoma after surgery. At 6 months, 32 of 206 (15.5%) eyes examined had glaucoma; at 12 months, 44 of 153 (28.8%) eyes examined had glaucoma. Median follow-up time was 5.8 months (range, 0.1 to 48 months). Mixed-breed dogs were at a significantly lower risk for glaucoma, compared with other breeds. Eyes with IOL placement were at a significantly lower risk for glaucoma, compared with eyes without IOL placement. Eyes with hypermature cataracts were at a significantly higher risk for glaucoma, compared with eyes with mature or immature cataracts. CONCLUSIONS AND CLINICAL RELEVANCE: Multiple factors appear to contribute to the onset of glaucoma in dogs after cataract surgery. Complications prohibiting IOL placement during cataract surgery may lead to a high risk of glaucoma development.

Entities:  

Mesh:

Year:  2000        PMID: 10844971     DOI: 10.2460/javma.2000.216.1780

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  7 in total

1.  Comparison of outcomes in cataractous eyes of dogs undergoing phacoemulsification versus eyes not undergoing surgery.

Authors:  Harathi Krishnan; Scott Hetzel; Gillian J McLellan; Ellison Bentley
Journal:  Vet Ophthalmol       Date:  2019-11-20       Impact factor: 1.644

2.  Cataract surgeon viewpoints on the need for novel preventative anti-inflammatory and anti-posterior capsular opacification therapies.

Authors:  Mahbubul H Shihan; Samuel G Novo; Melinda K Duncan
Journal:  Curr Med Res Opin       Date:  2019-08-28       Impact factor: 2.580

3.  Cataracts in 44 dogs (77 eyes): A comparison of outcomes for no treatment, topical medical management, or phacoemulsification with intraocular lens implantation.

Authors:  Christine C Lim; Shannan C Bakker; Cheryl L Waldner; Lynne S Sandmeyer; Bruce H Grahn
Journal:  Can Vet J       Date:  2011-03       Impact factor: 1.008

4.  Phacoemulsification and intraocular lens implantation in a Canada lynx with phacoclastic uveitis.

Authors:  Geneviève Lavallée; Stephanie C Osinchuk; Dennilyn Parker; Marina Leis; Lynne S Sandmeyer
Journal:  Can Vet J       Date:  2022-03       Impact factor: 1.075

Review 5.  Looking into the future: Gene and cell therapies for glaucoma.

Authors:  András M Komáromy; Kristin L Koehl; Shin Ae Park
Journal:  Vet Ophthalmol       Date:  2021-01-07       Impact factor: 1.644

Review 6.  The future of canine glaucoma therapy.

Authors:  András M Komáromy; Dineli Bras; Douglas W Esson; Ronald L Fellman; Sinisa D Grozdanic; Larry Kagemann; Paul E Miller; Sayoko E Moroi; Caryn E Plummer; John S Sapienza; Eric S Storey; Leandro B Teixeira; Carol B Toris; Terah R Webb
Journal:  Vet Ophthalmol       Date:  2019-05-20       Impact factor: 1.644

7.  Outcome of phacoemulsification in 71 cats: A multicenter retrospective study (2006-2017).

Authors:  Elena Fenollosa-Romero; Emily Jeanes; Ines Freitas; Andra-Elena Enache; Rachel Lockhart; Lorraine Fleming; Timothy N L Knott; Charlotte Dawson; Kerry Smith; Claudia Busse
Journal:  Vet Ophthalmol       Date:  2019-07-22       Impact factor: 1.644

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.